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Abstract
Background: Hirschsprung disease (HSCR), which is congenital obstruction of the bowel, results from a failure of
enteric nervous system (ENS) progenitors to migrate, proliferate, differentiate, or survive within the distal intestine.
Previous studies that have searched for genes underlying HSCR have focused on ENS-related pathways and genes
not fitting the current knowledge have thus often been ignored. We identify and validate novel HSCR genes using
whole exome sequencing (WES), burden tests, in silico prediction, unbiased in vivo analyses of the mutated genes
in zebrafish, and expression analyses in zebrafish, mouse, and human.
Results: We performed de novo mutation (DNM) screening on 24 HSCR trios. We identify 28 DNMs in 21 different
genes. Eight of the DNMs we identified occur in RET, the main HSCR gene, and the remaining 20 DNMs reside in
genes not reported in the ENS. Knockdown of all 12 genes with missense or loss-of-function DNMs showed that
the orthologs of four genes (DENND3, NCLN, NUP98, and TBATA) are indispensable for ENS development in
zebrafish, and these results were confirmed by CRISPR knockout. These genes are also expressed in human and
mouse gut and/or ENS progenitors. Importantly, the encoded proteins are linked to neuronal processes shared by
the central nervous system and the ENS.
Conclusions: Our data open new fields of investigation into HSCR pathology and provide novel insights into the
development of the ENS. Moreover, the study demonstrates that functional analyses of genes carrying DNMs are
warranted to delineate the full genetic architecture of rare complex diseases.
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Background
Hirschsprung disease (HSCR) is the most common form
of congenital obstruction of the bowel, with an incidence
of ~1/5000 live births. The incidence varies significantly
between ethnic groups, the highest being in Asia (2.8/
10,000 live births) [1]. HSCR results from a failure of the
neural crest (NC) cells, which give rise to the enteric
nervous system (ENS), to migrate, proliferate, differenti-
ate, or survive in the bowel wall, resulting in agangliono-
sis of the distal part of the gastrointestinal tract. This
results in clinically severe and sometimes life-
threatening bowel obstruction. As HSCR is a highly
heritable disorder, genetic variation (mutations) in the
genomes of these patients must largely explain disease
development. So far more than 15 HSCR susceptibility
genes, six linkage regions [1], and three associated loci
[2, 3] have been found. The genes identified belong to a
limited number of pathways relevant to the development
of the ENS, among which the RET and the endothelin
pathways are the most important. RET (encoding a tyro-
sine kinase) is the major gene with >80% of all known
mutations. These have been mainly identified in ~50% of
familial (mostly long-segment HSCR (L-HSCR), total
colonic aganglionsis (TCA)) and up to 20% of sporadic
(mostly short-segment HSCR (S-HSCR)) cases [4].
However, the identified genes and variants explain no
more than 25% of the overall genetic risk of all HSCR
cases [2, 3]. These findings indicate that the majority of
the disease risk must be due to as yet unidentified rare
or common variants in the known HSCR genes or, more
likely, variants in yet unknown genes, acting alone or in
combination.
The most popular approach to the analysis of whole
exome sequencing (WES) data includes selecting genes
that can be functionally linked to the pathways already
known to be involved in the disease under study. Vari-
ants in genes totally unlinked to the known genes or
pathways are largely neglected. This study aimed to
determine the contribution of rare exonic, non-
synonymous DNMs to HSCR without any a priori selec-
tion. Therefore, not only did we perform “standard”
exome sequencing analyses, followed by burden tests and
in silico prediction, but we also carried out an unbiased in
vivo analysis of the mutated genes in a zebrafish model.
Results
Identification of de novo mutations
In total 24 HSCR trios (Additional file 1: Table S1) were
included for WES analyses (Additional file 2: Figures S1
and S2). Sequencing metrics after the standard analytical
pipeline (Additional file 2: Figure S2) are detailed in
Additional file 3: Table S2 and Additional file 2: Figure
S3. Specifically, the coverage of the targeted sequences
per sample ranged from 18× to 74× (average 46×), and
the targeted exome was covered by at least ten sequence
reads which ranged from 65 to 98% (average 88%). All
these quality metrics or statistics showed data quality at
exonic regions that were comparatively good for trios
from different platforms or resources and justified our
unbiased searching of de novo mutations in the follow-
ing stages.
After validation, a total of 28 DNMs in 14 patients
were identified (Table 1; Additional file 1: Table S1;
Additional file 4: Table S3). The overall DNM rate per
individual was 1.2 per exome per generation (Poisson distri-
bution with λ = 1.2; Kolmogorov–Smirnov test, p = 0.893;
Additional file 2: Figure S4), which is in accordance with
the expected rate in the general population [5]. Several
studies found that patients have a significantly higher frac-
tion of loss of function (LOF) DNMs than healthy controls
[6, 7]. In our HSCR patient cohort, the LOF DNM rate (8
out of 24 trios) is significantly higher than that of healthy
trios (4 out of 54 trios; binomial test p = 0.011) or un-
affected siblings of neuropsychiatric patients (54 out of 677
trios; binomial test p = 0.001) (Additional file 5: Table S4)
[6, 8–11]; however, the enrichment of non-RET LOF
DNMs (3 out of 24 trios) in our trios is not significant.
These 28 DNMs were distributed among 21 genes. Eight
DNMs were in RET, the major HSCR gene [12]. The ob-
served RET DNM rate (0.33/trio) was significantly higher
(p < 2 × 10−16) than that modeled in the general population
(0.000133/trio) according to Samocha et al. [13].
One patient carried seven DNMs, two of which
(NCLN and DAB2IP) were mosaic (Additional file 2: Fig-
ure S5). This is in line with a recent report stating that
6.5% of all DNMs are mosaic and occur post-zygotically
[14]. Within the 24 patients, we looked for inherited rare
damaging variants in the 21 genes carrying DNMs.
Inherited damaging mutations were found in RET,
HMCN1, PLEKHG5, MAP4, SCUBE3, and KDM4A
(Additional file 6: Table S5). Neither de novo nor inher-
ited copy number variants (CNVs) were detected.
Determining pathogenicity of the DNMs in silico
We mainly followed the guidelines from Veltman and
Brunner [15] and MacArthur et al. [16] to determine the
pathogenicity of the variants and genes found in this
study. Firstly, to establish whether DNM genes carried
significantly more rare variants in HSCR patients than in
controls, we used WES data from the 20 eligible HSCR
trio-probands, 28 additional HSCR patients, and 212
control individuals to calculate the variation burden per
gene. Nine of the 21 genes (RET, KDM4A, HMCN1,
MAP4, NUP98, AFF3, COL6A3, CCR2, and CKAP2L)
were mutated in different sites in different HSCR
patients (Additional file 7: Table S6). Meta-analysis of
our gene burden tests showed that RET and CKAP2L
were enriched for rare damaging variants in HSCR
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(uncorrected p < 0.05; Table 2; Additional file 7: Table S6),
though our sample size is underpowered for genome-wide
statistical tests (Additional file 2: Figure S6). However,
crosschecking these 21 genes in another in-parallel HSCR
WES (190 cases, 740 controls) revealed that only RET was
significantly overrepresented with deleterious variants
(p < 0.001; A. Chakravarti, manuscript in preparation).
Besides the eight LOF mutations, six out of twelve
missense mutations were consistently predicted to be
deleterious (Additional file 8: Table S7). As for the seven
synonymous DNMs, we found no in silico evidence
indicating that those changes interfered with splicing
and/or RNA structure (Additional file 8: Table S7). After
checking those genes with DNMs against the ATGU’s
gene look-up server [13] and the Exome Aggregation
Consortium (ExAC) Browser [17], in total 11 genes
(Table 2) were identified as evolutionarily constrained
where variants are more likely to be deleterious [13].
Next we checked whether the genes with DNMs were
functionally related to each other and/or to the signaling
networks known to govern ENS development. Although
no direct in silico interactions were found among the 21
genes, ISG20L2 and MAP4 showed more indirect inter-
actions with other genes with DNMs than that expected
by chance (p = 0.0063 and p = 0.0167, respectively). A list
of 116 ENS-related genes (Additional file 9: Table S8)
was used to study the functional link between DNM
genes (other than RET) and ENS. Only a single inter-
action was identified (COL6A3 interacts with ITGB1).
Ingenuity Pathway Analysis identified additional direct
Table 1 De novo mutations in Hirschsprung disease probands
Trio Phenotype Gene De novo mutation Type MAF (dbSNP137/ESP6500/ExAC)a
1 L, F RET 3splicing9 + 1 Splicing N/N/N
RBM25 c.474C > T:p.L158L Synonymous N/N/N
2 L, F RET c.2511_2519delCCCTGGACC:p.S837fs Frameshift N/N/N
COL6A3 c.3327C > T:p.H1109H Synonymous 4.2E-4 (rs114845780)/N/1.2E-4
3 L, F RET c.1818_1819insGGCAC:p.Y606fs Frameshift N/N/N
4 L, F DAB2IP c.2339C > T:p.T780Mb Missense N/N/2.8E-3
ISG20L2 c.961G > A:p.G321R Missense N/N/N
MED26 c.675C > T:p.A225A Synonymous N/N/N
NCLN c.496C > T:p.Q166Xb Nonsense N/N/N
NUP98 c.5207A > G:p.N1736S Missense N/N/N
VEZF1 c.584C > T:p.S195F Missense N/N/N
ZNF57 c.570C > T:p.D190D Synonymous N/N/N
5 L, F RET c.1761delG :p.G588fs Frameshift N/N/N
SCUBE3 c.1493A > T:p.N498I Missense N/N/N
6 L, M AFF3 c.1975G > C:p.V659L Missense N/N/N
PLEKHG5 c.2628G > T:p.T876T Synonymous N/N/9.1E-6
7 L, M KDM4A c.26A > G:p.N9S Missense N/N/N
8 L, M MAP4 c.3351C > T:p.G1117G Synonymous N/N/9.2E-6
9 L, F RET c.1858 T > C:p.C620R Missense 0 (rs77316810)/N/N
10 TCA, M CKAP2L c.555_556delAA:p.E186fs Frameshift N/2E-5/2.5E-5
11 L, F RET c.409 T > G:p.C137G Missense N/N/N
HMCN1 c.10366G > A:p.A3456T Missense N/N/N
TUBG1 c.699 T > C:p.S233S Synonymous N/N/8.2E-6
12 L, F CCR2 c.848 T > A:p.L283Q Missense N/N/N
DENND3 c.1921delT:p.K640fs Frameshift N/N/N
13 L, F RET c.1710C > A:p.C570X Nonsense N/N/N
14 L, F RET c.526_528delGCA:p.R175del Non-frameshift N/N/N
TBATA c.157C > T:p.R53C Missense N/N/4.1E-5
Genes in bold indicate patients carrying de novo RET mutations. Underlines genes are genes giving a HSCR-like phenotype in zebrafish.
F female, L long-segment HSCR, M male, TCA total colonic aganglionsis
aMinor allele frequency (MAF) in dbSNP137, ESP database or ExAC database, with “N” standing for no data available.
bMosaic mutation
Gui et al. Genome Biology  (2017) 18:48 Page 3 of 13
and indirect relationships with ENS-related genes for
MAP4, COL6A3, RBM25, and TUBG1 (Additional file 2:
Figure S7). All genes carrying DNMs were either
expressed in human induced pluripotent stem cell
(iPSC)-derived enteric neuron precursors or in primary
murine enteric neuron precursors (Table 2).
Determining pathogenicity of the DNMs in vivo
Thirteen genes had a LOF or missense mutation but
were not obvious candidates for HSCR as there was no
previous report linking these genes to ENS development
or HSCR pathogenesis. We used the zebrafish model
system to further investigate the function of these genes
in ENS development. We used the model as previous
studies have shown that morpholino-mediated knock-
down of orthologs of known HSCR genes did result in
an HSCR-like phenotype in zebrafish [3, 18]. Except
CCR2, all 13 genes with nonsynonymous DNMs have
zebrafish orthologs. Splice-blocking morpholinos (SBMOs)
against the 12 genes were injected into Tg(-8.3phox2b:-
Kaede) transgenic zebrafish [19] embryos that express the
fluorescent protein Kaede in enteric neuron precursors and
differentiated enteric neurons, while its effect on gene tran-
scription was confirmed by quantitative PCR (qPCR)/RT-
PCR expression pattern. Initially, knockdown of five ortho-
logs (ckap2l, dennd3a and b, ncl1, nup98, and tbata)
resulted in a HSCR-like phenotype as enteric neurons were
absent in the distal intestine of embryos 5 days post-
fertilization (dpf) (Fig. 1a–e), while embryos injected with
5-nucleotide mismatch control morpholinos had normal
ENS development with enteric neurons present along the
entire length of the intestine (Fig. 1f–j). It was reported that
morpholinos might induce target-independent apoptosis
through p53 activation that leads to an unspecific off-target
phenotype [20]. To confirm the HSCR-like phenotype
observed in the morphants resulted from target-specific
knockdown, we co-injected the SBMOs with p53 morpho-
lino, which would inhibit p53 activity and thereby block the
unspecific apoptosis. As a result, the phenotype could not
be reproduced by ckap2l SBMO and p53 morpholino
co-injection (Fig. 1k), suggesting the phenotype observed
initially was an off-target effect. On the contrary, co-
injection of p53 morpholino with dennd3a and b, ncl1,
nup98, or tbata SBMOs resulted in the same phenotype
Table 2 Genes carrying de novo mutations
Gene Number of
amino acids
Co-occurrence
with RET DNM
Burden test meta-analyses
(uncorrected p value)
Gene constraint
prediction (AGTU; ExAC)a
Zebrafish ENS
phenotype
Gut expression
(human; mouse; zebrafish)b
PLEKHG5 1062 No 0.3997 No; No NT Yes; Yes; ND
KDM4A 1064 No 0.1190 No; Yes No Yes; Yes; ND
ISG20L2 353 No 0.4949 No; No No Yes; Yes; ND
HMCN1 5635 Yes 0.9789 No; No No Yes; Yes; ND
AFF3 1226 No 0.4745 No; Yes No Yes; Yes; ND
CKAP2L 745 No 0.0178 No; No No Yes; Yes: ND
COL6A3 3177 Yes 0.6398 No; No NT Yes; Yes; ND
CCR2 374 No 0.4745 No; No No Yes; Yes; ND
MAP4 1152 No 0.4851 No; Yes NT Yes; No; ND
SCUBE3 993 Yes 0.7133 Yes; Yes No Yes; Yes; ND
DENND3 1198 No 0.5977 No; No Yes Yes; Yes; Yes
DAB2IP 1189 No 0.9819 No; Yes No Yes; Yes; ND
RET 1114 - 0.0078 No; Yes Yes Yes; Yes; ND
TBATA 351 Yes 0.8028 NA; No Yes No; Yes; Yes
NUP98 1817 No 0.7243 No; Yes Yes Yes; Yes; Yes
RBM25 843 Yes 0.0846 Yes; Yes NT Yes; Yes; ND
TUBG1 451 Yes 1.0000 Yes; Yes NT Yes; Yes; ND
VEZF1 521 No 0.6717 No; Yes No Yes; Yes; ND
ZNF57 555 No 0.3808 No; No NT Yes; No; ND
NCLN 563 No 0.4949 No; No Yes Yes; Yes; Yes
MED26 600 No 1.0000 No; Yes NT Yes; Yes; ND
aGenes evolutionarily constrained as per AGTU’s server and ExAC database: “No” for not constrained, “Yes” for constrained, “NA” for not available.
bData from in-house human induced pluripotent stem cell-derived neural crest, mouse expression data, and RT-PCR and in situ hybridization in zebrafish; ND
not done.
NT not tested (gene carries synonymous mutation and/or has no ortholog in zebrafish)
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(Fig. 1l–o), indicating the phenotype was not caused by un-
specific apoptosis. qPCR analysis showed that the expres-
sion of dennd3a, dennd3b, nup98, and tbata was markedly
reduced in the SBMO-injected embryos (Additional file 2:
Figure S8). Intriguingly, there was no significant reduction
in ncl1 expression in the ncl1 SBMO-injected embryos.
Therefore, we further investigated it by performing RT-PCR
on individual embryos and found that there was a large
variation in ncl1 expression between embryos injected with
the SBMO, with some of them showing a clear reduction in
ncl1 transcript level (Additional file 2: Figure S9). Of the
zebrafish orthologs that did not show a specific HSCR-like
phenotype after SBMO injection, all demonstrated
significant reductions in expression except for aff3, scube3,
and vezf1a (Additional file 2: Figure S8). We verified the
results by repeating the knockdown experiment with a sec-
ond, non-overlapping translation-blocking morpholino
(TBMO) against dennd3a and b, ncl1, nup98, or tbata and
the HSCR-like phenotype was reproduced (data not
shown). Overall, from the morpholino knockdown experi-
ment we identified 4 out of 12 candidate genes that were
important for ENS development and caused a HSCR-like
phenotype when their functions were disrupted.
With the recent improvement in the CRISPR knockout
protocol in zebrafish, which enabled phenotype analysis
in guide-RNA (gRNA)-injected F0 larvae [21], we
decided to carry out CRISPR knockout of ckap2l,
dennd3a and b, ncl1, nup98, and tbata to further
strengthen our data obtained from morpholino knock-
down. We first tested the protocol by injecting ret gRNA
and observed loss of enteric neuron phenotype in 5-dpf
F0 larvae (data not shown). ckap2l gRNA did not cause
a HSCR-like phenotype (Fig. 1p), reaffirming the inter-
pretation that the initial observation in morpholino
knockdown was an off-target effect. CRISPR knockout
of dennd3a and b, ncl1, nup98, and tbata all resulted in
the loss of enteric neurons in 5-dpf larvae (Fig. 1q–t).
The presence of indel mutation at the target site was
confirmed by T7E1 assay (Additional file 2: Figure S10).
Therefore, we concluded that DENND3, NCLN, NUP98,
and TBATA orthologs’ loss of function disrupted ENS
development and caused a HSCR-like phenotype in vivo.
Temporal analysis using RT-PCR revealed zebrafish
orthologs (dennd3a, dennd3b, ncl1, and nup98) for
DENND3, NCLN, and NUP98 were maternally and
zygotically expressed from 0–120 hpf while the TBATA
ortholog (tbata) is only zygotically expressed from 24–
120 hpf (Additional file 2: Figure S11). Whole mount in
situ hybridization (WISH) analysis showed that the
orthologs for all four genes were expressed in distinct
spatial locations specifically in the intestine and the an-
terior central nervous system (CNS) from 24–96 hpf,
Fig. 1 Pathogenicity analysis in vivo by morpholino gene knockdown and CRISPR/Cas9 knockout in zebrafish. Morpholino knockdown of ckap2l,
dennd3, ncl1, nup98, and tbata resulted in a HSCR-like phenotype when compared to control (a–j). Kaede-expressing enteric neurons were absent
in the distal intestine at 5 dpf. The number of embryos with phenotype out of the total number of embryos observed is shown. Co-injection of
p53 morpholino reproduced the phenotype except ckap2l, indicating the loss of enteric neurons in dennd3, ncl1, nup98, and tbata knockdown
was not the result of p53-induced apoptosis (k–o). The results were verified by CRISPR/Cas9 knockout of ckap2l, dennd3a and b, ncl1, nup98, and
tbata, in which the HSCR-like phenotype was reproduced (p–t). Dotted lines outline the intestines. Asterisks indicate the position of the anus.
Arrows indicate the position where the aganglionic region begins. Scale bar = 200 μm. MO morpholino, nt nucleotide
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suggesting a role not only in ENS development but also
in the CNS (Fig. 2).
Mutation profile of HSCR patients
Out of the 14 patients with DNM, eight carried muta-
tions in RET and six in genes other than RET. Interest-
ingly, one of the patients with RET DNM also harbored
DNM in genes that recapitulate HSCR in zebrafish
(TBATA), suggesting that, in humans, mutations in
more than one gene might be necessary for the pheno-
type to develop. Among the six patients with no RET
DNM, two (HSCR4 and HSCR12; Table 1) harbored
functionally supported DNMs. Overall, we observed 33%
(8 out of 24) diagnostic rate for RET mutations in all our
patients, but 62.5% (5 out of 8) if considering only those
non-prescreened trio probands. This is consistent with
previous report on RET contribution to L-HSCR [4].
Besides, since both rare and common variants jointly
contribute to HSCR, we examined the genetic profile
(Additional file 6: Table S5) of our patients to assess the
genetic background on which the DNMs reside. Each pa-
tient was investigated for the presence/absence of the
common HSCR-associated RET allele (rs2435357T) [22]
as well as for the presence of rare variants (inherited from
unaffected parents) in a set of 116 ENS-related pre-
selected genes (Additional file 4: Tables S3; Additional file
9: Table S8). We did observe common RET risk alleles
and rare damaging mutations in ENS candidate genes in
all patients (Additional file 6: Table S5), regardless of their
DNM status. Whether common or rare RET risk alleles
and/or rare mutations in ENS genes in the background
contribute to the phenotype would need further research.
Discussion
Over the past years a large number of papers have been
published on de novo mutation screening in human
diseases. This has resulted in the identification of many
new disease-associated genes. Genes are considered as
true disease causing when there is a significant excess of
de novo mutations among unlinked patients. This works
well for diseases that are relatively homogeneous or for
which many patients can be investigated. For the more
heterogeneous rare diseases for which only small cohorts
are available this poses a problem. Often possible disease
causing genes are found in a single patient. How to de-
cide whether this finding is of importance? Expression of
the gene in the relevant tissues can be considered as
additional evidence, as is network analysis. However,
making strong statements for private disease genes is,
and will be, extremely difficult. It also results in a bias
towards genes in the known disease-causing gene
networks. Genes not fitting the current knowledge are
often discarded as uninteresting. In the current study we
wanted to take this all one step further.
Therefore, to assess if the mutated genes play a role in
ENS development, we performed two rounds of func-
tional analyses. We opted for an in vivo approach using
the zebrafish model system. We knocked down the ex-
pression of zebrafish orthologs of 12 of the 13 genes in
which loss-of-function or missense DNMs had been
identified. Nine genes were successfully knocked down
and four of them resulted in loss of neurons in the distal
gut. It was noted that in some morphants the proportion
of larvae displaying a HSCR-like phenotype was
comparatively low. Although in most cases we could
improve the efficacy by increasing the amount of mor-
pholino injected, this also led to a higher death rate and
more dysmorphic larvae caused by the general toxicity
of the morpholino. Therefore, we chose the dose that
caused the minimum death rate and dysmorphic rate
with slightly lower, but still valid, efficacy. It should also
be noted that in some of the morphants the gut
Fig. 2 Temporal and spatial expression patterns of zebrafish orthologs. Whole mount in situ hybridized embryos hybridized with antisense
riboprobes for dennd3a (a–d), dennd3b (e–h), ncl1 (i–l), nup98 (m–p), and tbata (q–t) at the indicated developmental stages. All columns show
lateral views. Intestinal expression for all genes is apparent from 48 hpf onwards. Scale bar = 500 μm
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development appeared to be affected. Perhaps it was not
surprising as from the in situ hybridization results some
of these genes seemed to be expressed in the surround-
ing intestinal tissues as well. Therefore, when hypothe-
sizing the function of these genes in ENS development,
in addition to the intrinsic effect on enteric neural crest
cells, one should not rule out the possibility of the
extrinsic influence via the intestinal tissues. Noteworthy,
the SBMOs targeting three of the orthologs (aff3,
scube3, and vezf1a) did not knockdown the target
transcripts as expected, highlighting the limitation of
morpholinos [23]. To strength our morpholino data we
opted for CRISPR knockout, which allowed phenotype
analysis in F0 larvae. The HSCR-like phenotype was
reproduced in the CRISPR knockout of dennd3a and b,
ncl1, nup98, and tbata. Although the presence of indel
mutation was confirmed by T7E1 assay in all larvae
injected with gRNA, the number of larvae displaying the
phenotype was relatively low. We suspected this was
mainly due to the varying CRISPR efficiency (number of
indels present in the target gene over the total number
of the target gene copy in a larva) between larvae.
For those four mutations from the newly validated
genes (DENND3, NCLN, NUP98, and TBATA), two of
them (NCLN:Q166* and DENND3:K640fs) are loss-of-
function mutations that disrupt gene translation; the
other two (NUP98: N1662S and TBATA:R53C) are pre-
dicted as highly deleterious by Polyphen2 and a logistic
regression model that combine different predicted scores
[24]. This in silico evidence (Table S8) strongly supports
the potential impact of the mutations on their genes
[15]; hence, we do not report any functional assay to
validate them in this study.
The finding of these four genes recapitulating HSCR
in zebrafish clearly demonstrates that genes that would
have never been followed up based on the usual gene
selection criteria should not be ignored. Using bioinfor-
matics prediction and statistics, we would have focused
on RET and CKAP2L as they were the only genes signifi-
cantly enriched for rare variants in patients.
We wondered whether any of these four genes could
be linked to the ENS or whether they play relevant roles
in neuronal development or NC-derived cell types in
general. In fact, by studying these genes in more depth
we noticed that all four, despite a lack of obvious
connection to the known ENS pathways, are involved in
the development of the CNS or the NC, making these
not as random as they might first appear.
DENN/MADD domain containing 3 (DENND3) is a
guanine nucleotide exchange factor (GEF) that is
involved in intracellular trafficking by activation of the
small GTPase RAB12 [25]. In zebrafish, Rab12 and other
Rab GTPases are highly expressed by pre-migratory NC
cells and their expression is dysregulated in Ovo1
morphant zebrafish that display altered migration of NC
cells [26]. Independently of RAB12, DENND3 also regu-
lates Akt activity, which is involved in the proliferation
and survival of enteric NC cells [25, 27].
Nicalin (NCLN) is a key component of a protein
complex that antagonizes Nodal signaling [28], which in
vertebrates is involved in induction of the mesoderm
and endoderm [29]. In contrast, inhibition of Nodal
signaling is required for the specification of human em-
bryonic stem cells into neuroectoderm, including the
NC [30, 31]. The antagonizing function of Nicalin on
Nodal signaling is therefore consistent with the NC spe-
cification required for ENS development.
NUP98 encodes a precursor protein that is autoproteo-
lytically cleaved to produce two proteins: NUP98 from the
N-terminus and NUP96 from the C-terminus [32]. A mis-
sense DNM was identified in the last exon of the NUP98
gene and therefore affects the NUP96 protein. As in
humans, zebrafish Nup96 is produced by cleavage of the
Nup98 precursor protein. Since morpholinos act on the
mRNA level, both nup98 and nup96 were targeted in our
zebrafish experiments. It is therefore unclear whether the
observed aganglionosis is caused by loss of Nup98 or
Nup96. NUP96 is one of approximately 30 proteins in the
nuclear pore complex (NPC) [33] and its expression level
regulates the rate of proliferation [34]. Two other mem-
bers of the NPC (Nup133 and Nup210) are involved in
neural differentiation in mice [35, 36]. Moreover, NUP96
interacts with NUP98 and NUP98 is involved in transcrip-
tional regulation of the HSCR genes SEMA3A, DSCAM,
NRG1, and the NRG1 receptor ERBB4 in human neural
progenitor cells [37]. Therefore, it is likely that loss of both
NUP proteins (NUP96 or NUP98) could contribute to
HSCR development.
The mouse ortholog of TBATA (Thymus, brain and
testes associated) is called Spatial and is highly expressed
during differentiation of several tissues [38]. These in-
clude the cerebellum, hippocampus, and Purkinje cells
in the brain, where TBATA/Spatial is expressed in early
differentiating neurons [39]. In mouse hippocampal neu-
rons, TBATA/Spatial is required for neurite outgrowth
and dendrite patterning [40].
The four newly identified HSCR candidate genes seem
to play a role in neuronal development and could poten-
tially be involved in HSCR (Fig. 3). This also suggests a
clear link between CNS and ENS development. This
does not come as a total surprise, as several known
HSCR genes (e.g., KBP, SOX10, NRG1, IKBKAP, ZEB2,
PHOX2B) are involved in both CNS and ENS patholo-
gies [2, 41–43] and the fact that HSCR is strongly
associated with Down syndrome.
Besides the fact that several HSCR/neuromuscular
genes are known to be associated with CNS defects, the
opposite is also described. Many neurological and
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psychiatric disorders are associated with constipation,
and sometimes defects in the ENS are reported [44]. For
instance, it has recently been described that mutations
in CDH8 result in a specific subtype of autism in
combination with gastrointestinal problems. A cdh8−/−
zebrafish recapitulates the human phenotype, including
increased head size, impairment of gastrointestinal mo-
tility, and reduction in post-mitotic enteric neurons [45].
Besides, searching “CNS” and “autism” in Phenolyzer
(http://phenolyzer.wglab.org/) returns two ENS genes,
APP [46] and MECP2 [47].
Given the fact that HSCR occurs together with neuro-
logical disorders more often than expected, it is not
surprising that dysfunction of these newly identified
neurological-related genes results in dysregulation of the
NC-derived cells that form the ENS, and hence in
HSCR. These data are further corroborated by the
expression patterns we observed for the orthologs of
these four genes in zebrafish embryos (Fig. 2), with all
four being expressed in both brain and gut.
Using zebrafish as a model we have experimentally
shown that some of the genes with de novo mutations
appear to be functionally or biologically linked with the
ENS. As the effect of de novo variants on the phenotype
may depend on the genetic background, it is tempting to
speculate that those genes that failed to reproduce the
HSCR phenotype in zebrafish could, in fact, contribute
to the disease in humans.
While statistical evidence of involvement in HSCR has
only been attained for RET, the functional studies pre-
sented here support the possible contribution of
DENND3, NCLN, NUP98, and TBATA to the disorder.
Finding a role for these genes in ENS development will
open new research avenues and enhance our knowledge
about ENS development and HSCR disease mechanisms.
Until now, we believed that the number of cellular
processes involved in the development of HSCR was
limited. Clearly this idea needs to be revisited as the
novel genes we identified are not directly linked to any
of the currently known HSCR gene networks.
Conclusions
Our data open new fields of investigation into HSCR
pathology and provide insight into the development of
both the ENS and CNS. Moreover, as a lesson for all
those who work on rare heterogeneous diseases, the
study demonstrates that functional analyses of genes
carrying DNMs is warranted to delineate the full genetic
architecture of rare complex diseases.
Methods
Study samples
Trios
A total of 24 trios (affected child and unaffected parents)
without family history of HSCR recruited in five differ-
ent centers were included for whole exome sequencing
Fig. 3 Newly identified genes in ENS development. All symbols represent proteins coded by genes known to be involved in HSCR or novel
genes identified in this study. The effect of NUP98 is shown by protein NUP96. The interaction effects between different proteins are illustrated by
four different lines representing binding, secreted/express, phosphorylation, and activation. ENCC enteric neural crest cell
Gui et al. Genome Biology  (2017) 18:48 Page 8 of 13
(WES). The patients were all non-syndromic. Five trios
were of Chinese origin whereas 19 were of Caucasian
ancestry. We prioritized the most/more severe and rarer
HSCR cases for this study, namely female patients with
long segment or total colonic aganglionosis. Sixteen out
of the 24 patients had previously tested negative for RET
damaging variants by traditional technologies. Charac-
teristics of the patients are presented in Additional file 1:
Table S1. Informed consent was obtained from all
participants.
Case–control
WES data from 28 additional sporadic HSCR patients
without sub-phenotype limitation (singletons) and 212
controls were used to check gene recurrence and assess
the gene burden for rare variants (Additional file 1:
Table S1).
Data generation
Whole exome sequencing
DNA samples were sequenced in four centers. The
exome-capture kit and sequence platforms used per cen-
ter are detailed in Table S2. Appropriate mapping tools
(Burrows–Wheeler aligner (BWA) for Illumina data and
Bfast for Solid data) were used to align sequence reads
to the human reference genome (build 19) [48].
Sequence quality was re-evaluated using the FastQC
toolbox, Picard’s metric summary, and the Genome
Analysis Toolkit (GATK) Depth-of-Coverage module.
After initial quality control (QC) all eligible sequences
were pre-processed for local indel realignment, PCR du-
plicate removal, and base quality recalibration [49].
Genome-wide SNP array
To determine copy number variants (CNVs) and regions
of homozygosity, DNA was hybridized to the Human-
Cyto SNP12 BeadChip (Illumina, San Diego, CA, USA)
according to standard protocols.
Variant calling and prioritization
Aligned reads from all sequenced samples were pre-
processed according to standard guidelines [49]. Variant
calling was done independently for Illumina reads or
Solid reads using the GATK unified Genotyper 2.0 [50].
To avoid mismatched regions across different capture
kits, calling was performed whole genome-wide without
limiting to any capture array. A special setting (allow po-
tentially miscoded quality scores) was used to make
color-spaced solid reads compatible to the program
(Broad institute). Raw variants (including single nucleo-
tide variants and short insertions/deletions) with individ-
ual genotypes and their affiliated quality scores were
stored in a standard VCF format after calling. Quality as-
sessment (QA) and QC were then adopted on a few sets
of variants (raw variants, exonic variants, rare variants)
to generate a confident variant set for downstream
prioritization (Additional file 1: Supplementary
methods). A clean variant set at exonic regions was
produced after variant-level and genotype-level QC. Rare
coding sequence variants were then prioritized by filter-
ing out those variants with minor allele frequency >0.01
in any of these public databases (dbSNP137, 1000
Human Genome project, and NHLBI Exome Sequen-
cing project). An automatic pipeline integrating GATK
[49], KGGSeq [51], Annovar [52], and Plink [53] was
used to generate the final set of qualified variants
(Additional file 2: Figure S1).
Identification of DNMs
WES DNM detection
Rare, exonic variants present in the probands but absent
in both parents were considered DNMs. To select puta-
tive DNMs (or de novo variations) the following criteria
were used: 1) minimal coverage of five in patients and
parents; 2) a minimal genotype quality score of 10 for
both patients and parents; 3) at least 10% of the reads
showed the alternative allele in patients; and 4) not more
than 10% of the reads showed the alternative allele in
parents. Subsequently all remaining DNM variants were
manually inspected using the Integrated Genome Viewer
(IGV) and classified into five different confidence ranks
according to their base-calling quality and strand bias.
The first two ranks of DNM candidates were selected
for validation by Sanger sequencing; while the other
three classes of candidates were re-evaluated by a model
trained from variants submitted for Sanger sequencing
(Additional file 2: Supplementary methods).
RET gene inspection
To guarantee that no de novo mutations had been
missed in the major HSCR gene, the depth of coverage
of each of the 21 exons of RET was manually inspected
for each patient. All exons with a coverage <10 were
Sanger sequenced. Mutation Detector software (Thermo
Fisher Scientific) was used to identify rare coding
sequencing mutations from raw Sanger sequences; any
mutation found in a trio proband was further checked in
his/her parents. Besides rare mutations, bi-allelic geno-
types for the common risk single nucleotide polymor-
phisms (IVS1 + 9494, rs2435357T) were extracted from
local databases or newly genotyped.
CNV detection
The Nexus®software program (Biodiscovery, El Segundo,
CA, USA) was used to normalize and analyze the SNP
array data as mentioned above. Loss is defined as the
loss of a minimum of five probes in a 150-kb region,
with a minimum log R ratio of –0.2. Gain is defined as
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the gain of a minimum of seven probes in 200-kb region,
with a minimum log R ratio of 0.15. The minimum
length of regions of homozygosity analysed was 2 Mb.
The identified CNVs were reviewed for pathogenicity
using the UCSC genome browser (http://genome.ucs-
c.edu/), the DGV database (http://dgv.tcag.ca/dgv/app/
home), the Decipher database (https://decipher.sanger.a-
c.uk/), and our in-house local reference database that
consists of 250 healthy controls and 250 individuals of
the general population.
Statistical tests
De novo mutation rate
All proven DNMs were classified into loss-of-function
(nonsense single nucleotide variants (SNVs), frame-shift
indels and splicing sites), missense SNVs, in-frame
indels, and synonymous SNVs. The counts of DNM per
trio were fitted to a Poisson distribution with lamda as
observed mean. De novo mutation rates were calculated
for these DNM subtypes and compared to 677 published
healthy trios and neurodevelopmental disease trios using
a binomial test [6–8, 10, 11, 54]. Given the per-gene
mutation rate in Samocha et al. [13], statistical over-rep-
resentation of mutations in all 24 genes were calculated
using Fisher’s exact test.
Gene-wide burden analysis
Genes with DNMs were further scrutinized for the pres-
ence of inherited rare damaging variants in the trios as
well as in HSCR singletons for whom WES data were
available. A detailed analytical protocol was shared
before running the association in each center. Briefly, ge-
notypes of rare damaging variants (as previously defined)
in genes carrying one or more de novo mutations were
extracted from raw sequencing reads. The CMC test in
the Rvtest package was used to collapse multiple variants
into the same gene (boundary defined using hg19
refgene) and compare overall burden between cases and
local matched controls [55]. P values were estimated by
asymptotic chi-square distribution. The gene-wise p value,
burden direction, and variant count per gene were
exported. Ultimately, the sample size weighted Z-score
method was used to conduct meta-analysis on gene-wise
summary statistics from three centers using the same
protocol.
Bioinformatics analysis
Variant-level implication
The impact of each DNM to its carrying gene was
predicted using several bioinformatics tools or databases.
The conservation of missense SNVs was predicted using
GERP and PhyloP across 29 different species. The dele-
teriousness of missense or nonsense SNVs were deter-
mined by a logit model incorporating five prediction
programs (Polyphen2, Sift, MutationTaster, PhyloP, and
likelihood ratio) [24]. Human Splicing finder was used
to predict whether DNMs causing synonymous change
or locating at splicing sites (exon ±2 bp) created or dis-
rupted splice sites [56]. To assess if synonymous DNMs
had any effect on the transcripts, we used RNAmute
[57]. Finally, ClinVar and PubMed were searched for the
same or similar mutations in the same gene that present
in healthy controls or other disease patients.
Gene-level implication
Evidence of gene-level implication was collected from
two aspects. First, those 24 genes carrying DNMs were
searched against databases (the ATGU’s server (https://
github.com/michaelchess/gene-lookup) and ExAC
browser (http://exac.broadinstitute.org/)) for recurrence
and constrained scores [13, 17]. Second, ENS candidate
genes/gene sets were curated (Additional file 1: Supple-
mentary methods) [58–60] and then linked to newly
identified genes using pathway or protein–protein inter-
action network information. Disease Association Pro-
tein–Protein Link Evaluator (DAPPLE) was used to test
whether the genes carrying DNMs in our study are func-
tionally connected to each other. The significance of ob-
served pathway enrichment and network connectivity
was evaluated empirically using randomly selected genes
from among genes of the same genomic size as the identi-
fied DNM genes. InWeb and Ingenuity Pathway Analysis
were used to detect direct and indirect protein interac-
tions between ENS-related genes and genes with DNMs.
Gene expression in the ENS
In order to test the involvement of the newly identified
genes in ENS development, in-house expression data
were shared from other parallel projects in the Hong
Kong and Rotterdam centers. The first expression data-
set was from RNA sequencing on an iPSC-induced en-
teric neural crest cell (ENCC) for a HSCR patient; the
second and third expression datasets were from micro-
array chips on embryonic mouse gut and ENCC.
Zebrafish
Tg(-8.3phox2b:Kaede) transgenic zebrafish (Danio rerio)
embryos were obtained from natural spawning. Mainten-
ance of zebrafish and culture of embryos were carried
out as described previously [61]. Embryos were staged
by hours (hpf ) or days (dpf) post-fertilization at 28.5 °C.
Gene knockdown by antisense morpholinos
Antisense morpholinos (MOs; Gene Tools LLC) target-
ing the zebrafish orthologs of the candidate genes, by
blocking either translation or splicing, were microin-
jected to one- to four-cell stage Tg(-8.3phox2b:Kaede)
transgenic zebrafish embryos as previously described
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[19]. For candidate genes that are duplicated in the zeb-
rafish genome, morpholinos targeting all paralogs were
co-injected. A standard control MO and 5-nucleotide
mismatch control MOs for ckap2l, dennd3a, dennd3b,
ncl1, nup98, and tbata were used as negative control.
Embryos were raised to 5 dpf, analyzed, and imaged
under a stereo fluorescence microscope (Leica MZ16FA
and DFC300FX). An HSCR-like phenotype was defined
as the absence of enteric neurons in the distal intestine
in 5-dpf embryos. Sequences and dosages of all MOs
used are included in Additional file 10: Table S9.
Gene knockout by CRISPR/Cas9
The design and synthesis of gRNA were carried out as
described [62]. Briefly, CRISPRscan (http://www.crisprs-
can.org/) was used to design gRNA sequences against
ckap2l, dennd3a, dennd3b, ncl1, nup98, and tbata.
Designs with high predicted efficiency and low predicted
off-target effects were chosen. DNA templates for gRNA
synthesis were generated by PCR fill-up reaction [62]
and the gRNAs were synthesized using a MEGAshort-
script™ T7 Transcription Kit (Invitrogen). gRNA (150
pg) was co-injected with recombinant 667 pg Cas9 pro-
tein to one-cell stage Tg(phox2b:kaede) embryos. For
dennd3a and dennd3b knockout 75 pg of each gRNA
was co-injected with Cas9. The injected larvae and un-
injected control were cultured to 5 dpf for phenotype
checking and imaging. Each larva was collected separ-
ately for genomic DNA extraction and T7E1 assay to
confirm the presence of indel mutation as described pre-
viously [21]. In brief, the genomic region flanking the
gRNA target site was amplified by PCR. The PCR prod-
uct was denatured and slowly re-annealed to allow the
formation of a heteroduplex. The re-annealed PCR prod-
uct was digested with T7 endonuclease I (New England
Biolab) at 37 °C for 45 min and then resolved by 2%
agarose gel electrophoresis. The sequences of gRNAs
and primers are listed in Additional file 11: Table S10.
Expression analysis
To confirm the target genes were successfully knocked
down, total RNA was extracted from 1-dpf embryos
(n = 50) injected with the splice blocking MO using
RNA Bee (Amsbio) and cDNA were reverse tran-
scribed using a iScript cDNA Synthesis Kit (Bio-rad).
qPCRs were performed using a KAPA Sybr® Fast qPCR
Kit (KAPA Biosystems; see Additional file 12: Table
S11 for primer details) and the expression of the target
gene was normalized by the mean expression of two
housekeeping genes (elfa and actb). The relative
expression of the target gene in the splice blocking
MO-injected embryos to the control MO-injected
embryos was determined by the Livak method [63].
To determine the temporal expression of the zebra-
fish ortholog, RT-PCR was performed at various time
points with primers used to amplify a segment of the
open reading frame of each gene. To determine the
spatial expression patterns of dennd3a, dennd3b, ncl1,
nup98, and tbata, antisense digoxigenin-labeled probes
for both genes were generated and whole-mount in
situ hybridization was performed as described by
Thisse et al. [64].
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